公司資料
Acrivon Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ACRV
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.05 USD (+5.13%)
收盤價
最後更新: 2026年8月17日
67.2M USD
市值
股價為何變動
As of Aug 17, 2026, ACRV closed up 5.13% at $2.05. No new same-company headline was identified in the current news window.
公司概覽
Generative Phosphoproteomics Platform
Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines.
ACR-368
ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and development both with and without biomarker-based patient selection.
ACR-2316
ACR-2316 is a dual WEE1 and PKMYT1 inhibitor designed through the AP3 platform. Early clinical development is prioritizing tumor types predicted to depend on the targeted cell-cycle pathways.
未來催化劑
- A simultaneous interim analysis and data update from both all-comer serous endometrial cancer arms of the ACR-368 Phase 2b study are expected in the second half of 2026.
- Acrivon expects readiness for a Phase 3 confirmatory study of ACR-368 with PD-1 therapy by mid-2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。